A safety study of Albumex® 5, a human albumin solution produced by ion exchange chromatography

Vox Sanguinis

Volumn 70, Issue 4, 1996, Pages 198-202

  Wolf, M ^a   Kronenberg, H ^b   Dodds, A ^c   Miach, P ^d   Isbister, J ^e   Levidiotis, M ^f   Dear, K ^g  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d AUSTIN HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f CSL LIMITED   (Australia)

^g UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMEX 5; BILIRUBIN; HUMAN ALBUMIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FATIGUE; FEMALE; HEMATURIA; HOT FLUSH; HUMAN; HUNGER; INTRAVENOUS DRUG ADMINISTRATION; ION EXCHANGE CHROMATOGRAPHY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTIGO;

EID: 0029943642     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1996.tb01326.x     Document Type: Article

References (17)

1. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68: 459.
2. Guidelines for the Reporting of Adverse Drug Reactions by Pharmaceutical Companies. Therapeutic Goods Administration, July 1991.
3. British Committee for Standards in Haematology: Guidelines for the clinical use of blood cell separators. Clin Lab Haematol 1980;12:141-158.
4. Beckman EM, Hillyer CD: Transfusion of plasma and plasma derivatives; in Hoffman R, Benz EJ Jr, Shattil SJ, et al (eds): Haematology: Basic Principles and Practice. New York, Churchill Livingstone, 1991, pp 1527-1532.
5. Subcommittee of the Victorian Drug Usage Advisory Committee: Human albumin solutions; consensus statements for use in selected clinical situations. Med J Aust 1992;157:340-343.
6. French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome: Role of replacement fluids. Ann Neurol 1987;22:753-761.
7. Ghosh S, Paton L: Complications of therapeutic plasma exchange. Clin Lab Haematol 1985;7: 219-224.
8. Editorial: Hazards of apheresis. Lancet 1982;ii: 1025-1026.
9. Zieselman EM, Bongiovanni MB, Wurzel HA: The complications of therapeutic plasma exchange. Vox Sang 1984;46:270-276.
10. Huestis DW: Mortality in therapeutic haemapheresis. Lancet 1983;1:1043.
11. Sutton DMC, Nair RC, Rock G, Canadian Apheresis Study Group: Complications of plasma exchange. Transfusion 1989;29:124-127.
12. Tullis JL: Albumin. 1. Background and use. JAMA 1977;237:355-360.
13. Van Rosevelt RF, Bakker JC, Sinclair DM, Danen J, Van Mourik JA: Bradykinin-mediated hypotension after infusion of plasma-protein fraction. J Lab Clin Med 1982;100:288-295.
14. Bakker JC, Stekkinger P, Nuizens JH, Duivis-Vorst R, Hack CE: Detection of prekallikrein activator bound to Cl-esterase inhibitor in albumin solutions. Annu Rep Dr Karl Landsteiner Found 1989;3-5.
15. Curling JM, Berglof JH, Lindquist LO, Eriksson S: A chromatographic procedure for the purification of human plasma albumin. Vox Sang 1977;33:97-107.
16. Yap HB, Young IF, Micucci V, Herrington RW, Turner PJ, Davies JR: Development of a process for the preparation of human serum albumin using chromatographic methods. Biotechnol Blood Products 1993;227:143-149.
17. Friesen AD, Janzen RG, Bees WCH: Biochemical and clinical studies of human albumin (5%) produced by industrial scale ion exchange chromatography. (abstract). Congress of International Society Blood Transfusion, 1988, p 69.